← Back to Search


Palliative Care for Blood Cancer (PALS_CT Trial)

Led By Reanne Booker, PhD(c)
Research Sponsored by Alberta Health Services, Calgary
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Family Caregivers: Family caregivers of patients with a clinical diagnosis of hematologic malignancy with scheduled hematopoietic stem cell transplantation or chimeric antigen receptor (CAR) T-cell therapy
Patients: Clinical diagnosis of hematologic malignancy with scheduled hematopoietic stem cell transplantation or chimeric antigen receptor (CAR) T-cell therapy
Screening 3 weeks
Treatment Varies
Follow Up 5 years
Awards & highlights

PALS_CT Trial Summary

This trial will compare early palliative care to standard care for patients and their family caregivers undergoing hematopoietic stem cell transplantation for blood cancers.

Who is the study for?
This trial is for patients with blood cancers like leukemia, lymphoma, or multiple myeloma who are scheduled for stem cell transplants or CAR-T therapy. They must understand English well enough to complete questionnaires. Their family caregivers can also join if they're in close contact at least twice a week and meet similar language criteria.Check my eligibility
What is being tested?
The PALS_CT study is testing whether getting palliative and supportive care early on helps improve the quality of life for patients undergoing stem cell transplants or CAR-T therapy, as well as their family caregivers, compared to standard care.See study design
What are the potential side effects?
Since this trial focuses on palliative and supportive care rather than direct medical treatments, side effects may not be applicable in the traditional sense. However, participants might experience emotional or psychological responses to discussions about their illness and future.

PALS_CT Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
I am a family caregiver for someone with blood cancer scheduled for stem cell transplant or CAR T-cell therapy.
I am diagnosed with a blood cancer and scheduled for a stem cell transplant or CAR T-cell therapy.
I have a caregiver who sees me in person at least twice a week.

PALS_CT Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Patient quality of life
Secondary outcome measures
Family caregiver quality of life
Patient and family caregiver prognostic understanding
Patient symptom burden
Other outcome measures
1 year overall survival
5 year overall survival

PALS_CT Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Palliative and Supportive Care InterventionExperimental Treatment1 Intervention
Participants randomized to the intervention arm will meet (either by phone or Zoom contingent upon participant preference) with a palliative care nurse practitioner or palliative care physician. During the first meeting, pre-transplant/CAR T-cell therapy, content will focus on the provision of information and education, including: a description of palliative and supportive care, symptom management, advance care planning, prognostic and illness understanding and treatment expectations, and coping strategies. All subsequent visits will include, at minimum, these topics. All meetings will be audio-recorded using a handheld audio-recorder; the record feature of Zoom will not be utilized. Participants in the intervention arm will meet with a member of the study team (palliative care nurse practitioner or palliative care physician) one to two times weekly, or more frequently if requested by the patient and/or family caregiver, until 3 months post-transplant/CAR T-cell therapy.
Group II: Standard CareActive Control1 Intervention
Standard care will involve the usual care that patients undergoing HSCT/CAR T-cell therapy would be expected to receive, including palliative care consultation as needed or upon request. Palliative care interventions beyond what are provided in the study will be tracked in both the intervention and the standard care arms.

Find a Location

Who is running the clinical trial?

University of VictoriaOTHER
56 Previous Clinical Trials
11,339 Total Patients Enrolled
Alberta Cancer FoundationOTHER
17 Previous Clinical Trials
5,481 Total Patients Enrolled
1 Trials studying Leukemia
60 Patients Enrolled for Leukemia
Alberta Health Services, CalgaryLead Sponsor
13 Previous Clinical Trials
2,449 Total Patients Enrolled

Media Library

Leukemia Research Study Groups: Standard Care, Palliative and Supportive Care Intervention

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

To what extent is the pool of participants being expanded for this clinical trial?

"Affirmative, clinicaltrials.gov shows that this medical trial is presently looking for individuals to take part in the study. This investigation was first posted on April 8th 2022 and its details were recently updated on the same day. Approximately 152 patients are needed for the research which will be conducted at a single site."

Answered by AI

Are individuals able to join the program currently?

"Affirmative. The details listed on clinicaltrials.gov verify that this trial, which was first made public on April 8th 2022, is currently recruiting patients. 152 individuals are needed to be signed up from 1 medical centre."

Answered by AI
Recent research and studies
~51 spots leftby Apr 2025